Clinical Trials Directory

Trials / Completed

CompletedNCT05506748

Association Between Preoperative HALP and Immediate Postoperative Outcomes

Association Between Preoperative HALP and Immediate Postoperative Outcomes in Patients Undergoing Pancreaticoduodenectomy

Status
Completed
Phase
Study type
Observational
Enrollment
22 (actual)
Sponsor
Chitwan Medical College · Academic / Other
Sex
All
Age
15 Years – 80 Years
Healthy volunteers

Summary

Multiple inflammation-based prognostic scores have been developed for the prediction of perioperative morbidity and mortality following pancreaticoduodenectomy (PD). Preoperative "Hemoglobin, Albumin, Lymphocytes and Platelets index (HALP)" is one of the promising inflammatory markers that has emerged as a predictor of postoperative survival. To date, no study has been done with preoperative HALP to predict 30days morbidity and mortality. Is there any association between Preoperative HALP (hemoglobin, albumin, lymphocyte, and platelet) and 30 days post operative morbidity and mortality in patients undergoing Pancreaticoduodenectomy?

Detailed description

General Objective: To assess the association between preoperative HALP and immediate postoperative outcome among patients undergoing PD. Specific Objectives: 1. To identify the magnitude of immediate post-operative morbidity and mortality in patients undergoing PD. 2. To evaluate the descriptive measurement of preoperative Hemoglobin, Albumin, Lymphocytes, Platelets and HALP among patients undergoing PD. 3. To compare the preoperative HALP with morbidity and mortality among patients undergoing PD. Operational Definition: 1. Immediate postoperative time - was taken as 30days following surgery. 2. Morbidity- was defined by Clavién-Dindo20 grading for the surgical complication and DGE,21 POPF,22 and PPH23 -according to International Study Group of Pancreatic Surgery (ISGPS) grading. 3. Mortality- survival within 30days. 4. Level of preoperative HALP- normality test was done via SPSS and data of HALP followed normal Gaussian distribution. So, mean was used for the calculation of cut off value as 35.83. And, patients were divided into low HALP (≤35.83) group and high HALP (\>35.83) group respectively

Conditions

Interventions

TypeNameDescription
OTHERpantients undergoing pancreaticoduodenectomyThe study includes all the cases who underwent pancreaticoduodenectomy for carcinoma head of the pancreas, distal cholangiocarcinoma, periampullary and duodenal cancer.

Timeline

Start date
2021-04-20
Primary completion
2022-04-20
Completion
2022-04-20
First posted
2022-08-18
Last updated
2022-08-18

Locations

1 site across 1 country: Nepal

Source: ClinicalTrials.gov record NCT05506748. Inclusion in this directory is not an endorsement.